AstraZeneca Looks To Take On GSK And Merck In Endometrial Cancer With Imfinzi Nod

The FDA has approved the UK firm's checkpoint inhibitor to treat patients whose cancer is mismatch repair deficient (dMMR). The next challenge is to have a treatment for the remaining 70-80% of endometrial cancer patients with mismatch repair proficient (pMMR) disease.

Astrazeneca
• Source: Shutterstock

AstraZeneca PLC's PD-L1 inhibitor Imfinzi has secured approval in the US for endometrial cancer, providing competition for GSK plc's checkpoint inhibitor Jemperli and Merck & Co., Inc.'s behemoth Keytruda.

The US Food and Drug Administration has given the green light to the AstraZeneca therapy in combination with the chemotherapies carboplatin and paclitaxel followed by Imfinzi (durvalumab) monotherapy for adults with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immuno-oncology

More from Anticancer